|
Título:
|
Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
|
|
Autores:
|
Yadav, Monika ;
Guzmán Aránguez, Ana Isabel ;
Pérez de Lara, María Jesús ;
Singh, Mandeep ;
Singh, Joga ;
Kaur, Indu Pal
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Elsevier, 2019-05-10
|
|
Dimensiones:
|
application/pdf
|
|
Nota general:
|
cc_by_nc_nd
info:eu-repo/semantics/openAccess
|
|
Idiomas:
|
|
|
Palabras clave:
|
Estado = Publicado
,
Materia = Ciencias Biomédicas: Medicina: Oftalmología
,
Materia = Ciencias Biomédicas: Óptica y optometría: Anatomía ocular
,
Materia = Ciencias Biomédicas: Farmacia: Bioquímica
,
Tipo = Artículo
|
|
Resumen:
|
Primary treatment for glaucoma relies on chronic instillation (daily) of intraocular pressure (IOP) lowering eye drops. Present study tends to develop and assess a novel sustained release bimatoprost loaded nanovesicular (BMT-NV) - thermosensitive in-situ gelling implant (BMT-NV- GEL-IM), for subconjunctival delivery. BMT-NVs developed using novel composition and method of preparation, (IPA/700/DEL/2014) and industrially viable methodology were characterized and evaluated comprehensively for ocular suitability. Their incorporation into an in-situ gelling formula was safe (in vitro and in vivo) and stable upon sterilization. Autoclavability was an important consideration, as a preservative-free, single-use BMT-NV- GEL-IM will avoid side- effects associated with repetitive application of drops containing preservatives like benzalkonium chloride (BAK). An extended in vitro release of BMT (80.23%) was observed for 10 days while the IOP lowering effect extended over 2 months with single subconjunctival injection of BMT-NV-GEL-IM in rats. No clinical signs of irritation, inflammation, or infection were observed in any injected eye, throughout the study, as also confirmed by histology. Furthermore, single administration of BMT-NV-GEL as topical drop lowered the IOP over 5 days. Presence of significant diffuse fluorescence in confocal microscopy of internal eye tissues post-in vivo application, as subconjunctival implant, even after 2 month and eye drops upto1 week provide direct evidence of successful sustained delivery. We thus provide an improved modality for antiglaucoma medication in patients who are challenged to adhere to a regimen of daily eye drops.
|
|
En línea:
|
https://eprints.ucm.es/55831/7/Guzman%20Aranguez_Paper-45-Eprint.pdf
|
